24 November 2017
News and Views
Links and Services
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease, reports the most recent issue of the Alimentary Pharmacology & Therapeutics.
The efficacy of adalimumab in maintaining remission in Crohn's disease patients may wane over tim
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors